Rumor vs Truth: Gastroesophageal Reflux Disease (GERD)

Rumor vs Truth: Gastroesophageal Reflux Disease (GERD)

Heartburn headlines, ranitidine recalls, and “once you start a PPI, you’re on it for life” warnings… which GERD claims actually hold up? Just in time for Thanksgiving and GERD Awareness Week, get the evidence on acid reflux medications.

In this episode, hosts Don Weinberger and Steve Small separate fact from fiction about GERD and the medications used to treat it, along with help from gastroenterology expert Dr. Nina Pascua.

  • 🔥 Does GERD always mean lifelong meds?
  • 🧪 Do H2-blockers cause cancer… and what’s up with ranitidine’s comeback?
  • 🔀 Do you really have to overlap an H2-blocker and a PPI when switching?
  • ⚖️ Are H2-blockers safer than PPIs long-term?

No need to swallow these claims whole… we’re tracing every burning rumor back to the evidence.

They’ll share research and insights into some interesting claims including:

  • Most GERD cases only need short-term treatment
  • H2-blockers cause cancer
  • Patients must overlap regimens when switching from an H2-blocker to a PPI
  • H2-blockers are safer than PPIs long-term
  • Plus, quick clinical insights on PPIs and dementia, and intermittent vs. continuous IV PPIs for bleeding ulcers.

🏷️ Use code rvt1026b at checkout for 10% off a new or upgraded subscription.

 

TRC Healthcare Editor Hosts:

  • Stephen Small, PharmD, BCPS, BCPPS, BCCCP, CNSC
  • Don Weinberger, PharmD, PMSP

 

Guest:

  • Nina Pascua, MD, PharmD, MSCE, MBA

 

CE Information:

None of the speakers have anything to disclose. 

TRC Healthcare offers CE credit for this podcast for subscribers at our platinum level or higher. Log in to your Pharmacist’s Letter, Pharmacy Technician’s Letter,or Prescriber Insights account and look for the title of this podcast in the list of available CE courses.

Claim Credit

 

The clinical resources related to this podcast are part of a subscription to Pharmacist’s Letter, Pharmacy Technician’s Letter, and Prescriber Insights:

 

Don’t miss out! Subscribe today to stay ahead with trusted insights and tools:

🏷️ Use code rvt1026b at checkout for 10% off a new or upgraded subscription.

 

Rumor vs Truth is a production of TRC Healthcare.

🗪 Send us Fan Mail

Email us: [email protected]

The content of this podcast is not intended to be a substitute for professional medical advice, diagnosis, or treatment.

Find the show on YouTube by searching for ‘TRC Healthcare’ or clicking here.

Learn more about our product offerings at trchealthcare.com.

Click here to listen to all podcast episodes.

Listen Now:

Transcript:

This transcript is automatically generated.

00:00:05 Narrator

Welcome to Rumor vs Truth, your trusted source for facts, where we dissect the evidence behind risky rumors and reveal clinical truths.

00:00:13 Narrator

Today, we’ll put out the fire on some burning claims about GERD.

00:00:21 Don Weinberger

All right, Steve, Thanksgiving is around the corner.

00:00:24 Don Weinberger

And I gotta ask you,

00:00:27 Don Weinberger

How many plates are you scarfing down?

00:00:29 Don Weinberger

Be honest.

00:00:32 Steve Small

Well Don.

00:00:32 Steve Small

I do try to pace myself, of course, until the pie comes out and then it’s really every pharmacist for themselves.

00:00:39 Don Weinberger

Well, that is perfect timing because Thanksgiving week is also gastroesophageal reflux disease or GERD awareness week from November 22nd to 28th.

00:00:50 Steve Small

And I’m glad we have that acronym done because that condition can be a mouthful.

00:00:55 Don Weinberger

Yep, I’ll be using that a lot.

00:00:57 Don Weinberger

And I had a few GERD puns ready, but I was worried they would just come back up.

00:01:05 Steve Small

Oh, gross.

00:01:07 Steve Small

Please keep them down, at least for the first five minutes here.

00:01:10 Don Weinberger

Okay, no promises though.

00:01:11 Don Weinberger

I do have a burning desire to get started.

00:01:15 Steve Small

And there it is.

00:01:16 Steve Small

I’m Steve the pharmacist.

00:01:18 Don Weinberger

And I’m Don the pharmacist.

00:01:19 Don Weinberger

In this episode, we’re looking at GERD claims that people tend to swallow whole, whether they should or not.

00:01:26 Steve Small

And before we dig in, we are grateful this holiday season that this podcast offers continuing education credit for pharmacists, pharmacy technicians, prescribers, and nurses.

00:01:37 Don Weinberger

That’s right.

00:01:38 Don Weinberger

Just log into your Pharmacist’s Letter, Pharmacy Technician’s Letter, or Prescriber Insights account and search to see courses for this title.

00:01:45 Steve Small

And for the purposes of disclosure today, none of the speakers have anything to disclose.

00:01:50 Steve Small

And you know, we probably should explain this condition, Don, since

00:01:54 Steve Small

Some of the audience may be asking, what’s the word on GERD here?

00:01:58 Don Weinberger

Nice.

00:01:59 Don Weinberger

So many patients know acid reflux.

00:02:03 Don Weinberger

That’s where the stomach acid backs up into the esophagus, causing that classic heartburn symptom.

00:02:09 Don Weinberger

And GERD is when that reflux causes troublesome symptoms or complications, often heartburn or regurgitation, two or more days a week.

00:02:19 Don Weinberger

And that’s not the only thing on the menu.

00:02:20 Don Weinberger

Other symptoms can occur too, such as coughing or hoarse voice.

00:02:25 Don Weinberger

And over time, GERD can damage the esophagus.

00:02:28 Don Weinberger

And what’s that look like?

00:02:29 Don Weinberger

Well, erosions, ulcers, narrowing, and even something we call Barrett’s esophagus, which is a precancerous change in the esophageal lining.

00:02:39 Steve Small

Yeah, pretty serious stuff.

00:02:40 Steve Small

And that’s why we have meds that reduce stomach acid and decrease GERD symptoms and those risks.

00:02:46 Steve Small

So popular ones are proton pump inhibitors, such as omeprazole and pantoprazole.

00:02:51 Steve Small

We like to call them PPIs.

00:02:53 Steve Small

And then histamine 2 or H2 receptor blockers, such as famotidine and cimetidine.

00:02:58 Don Weinberger

Yep.

00:02:59 Don Weinberger

And there’s two sides to the coin or plate when it comes to GERD.

00:03:04 Don Weinberger

On one side, the meds can be effective and even essential for some patients, but there tends to linger that fear and folklore around them that unfortunately has grown bigger than the evidence.

00:03:16 Steve Small

Indeed.

00:03:17 Steve Small

And data show about one in four people who start a PPI are still taking one a year later.

00:03:23 Steve Small

And in one large look at ambulatory visits, nearly two-thirds of PPI users had no clear indication for even using one.

00:03:32 Don Weinberger

So a short-term fix with a PPI can quietly turn to a decades-long habit.

00:03:39 Don Weinberger

But you can see how it’s easy to swing the other way and stop a med someone truly needs.

00:03:45 Steve Small

Exactly.

00:03:46 Steve Small

And today we’re looking at who needs long-term acid suppression, which safety concerns hold up, and how to switch or even stop these meds safely.

00:03:54 Steve Small

So here’s what’s on the menu, Don.

00:03:56 Steve Small

For appetizers, we’re going to see whether GERD always means lifelong meds.

00:04:01 Steve Small

Next, whether H2 blockers cause cancer and what’s up with ranitidine’s comeback.

00:04:07 Steve Small

Then our expert guest weighs in on overlapping an H2 blocker and a PPI when switching.

00:04:12 Steve Small

And for dessert, whether H2 blockers are safer than PPIs for the long haul.

00:04:19 Don Weinberger

Delicious.

00:04:20 Don Weinberger

And don’t forget the very end, Fast Facts, our quick toast of the evidence.

00:04:25 Don Weinberger

We’ll tackle whether PPIs cause dementia, plus whether intermittent or continuous versus continuous IV PPIs are better for bleeding ulcers.

00:04:33 Steve Small

Those claims are going to be a lot to digest.

00:04:37 Don Weinberger

Let’s hope they go down easier than that second slice of pie.

00:04:41 Steve Small

Well, let’s tuck in and get started.

00:04:43 Steve Small

With a worry patients have right after their first prescription, once I start this pill, am I on it for life?

00:04:50 Steve Small

So the claim here is most GERD cases only need short-term treatment.

00:04:56 Don Weinberger

Yeah, so working in the pharmacy, this comes up all the time, ad nauseam even.

00:05:03 Don Weinberger

Someone will come up

00:05:05 Don Weinberger

pick up a PPI refill and say, unfortunately, I guess I’m on this forever.

00:05:10 Don Weinberger

Well, Steve, is it actually true?

00:05:12 Steve Small

Well, the good news is usually not, but it does depend on the patient.

00:05:16 Steve Small

So for severe erosive esophagitis, the American College of Gastroenterology or ACG recommends staying on a PPI indefinitely or considering things like anti-reflux surgery.

00:05:29 Steve Small

But GERD with structural changes such as Barrett’s esophagus and strictures

00:05:33 Steve Small

are also on that keep going list too.

00:05:37 Don Weinberger

Okay, so interesting.

00:05:39 Don Weinberger

What about the other end of the spectrum?

00:05:41 Steve Small

Right, with milder disease, guidelines suggest that if classic GERD fully responds to an 8 or even 12 week PPI course, it’s reasonable then to try stopping it and seeing how the patient does.

00:05:52 Steve Small

And shorter courses can be used for things like dyspepsia.

00:05:56 Don Weinberger

Okay, so

00:05:59 Don Weinberger

I guess, can patients actually stop PPIs cold turkey or do they need a taper?

00:06:05 Steve Small

Well, I do have an early holiday gift you on that, Don, but you’re going to have to stay tuned.

00:06:10 Don Weinberger

Oh yeah, me and the audience are going to hold you to that one and we’ll see if we can be patient for it.

00:06:15 Don Weinberger

So back to it.

00:06:17 Don Weinberger

When patients stop these meds, lifestyle changes help keep symptoms controlled.

00:06:22 Don Weinberger

For example, ACG strongly recommends weight loss.

00:06:26 Don Weinberger

I know no fun.

00:06:27 Don Weinberger

but weight loss for overweight and obese patients with GERD.

00:06:31 Don Weinberger

How does that work?

00:06:32 Don Weinberger

So extra weight, especially around the belly, pushes the stomach contents up towards the esophagus and makes that valve that supposed to close in all that acid relax more often, which is how most reflux episodes actually start.

00:06:46 Don Weinberger

So I guess it’s like overstuffing a suitcase.

00:06:50 Don Weinberger

Sooner or later, something’s going to come out on top.

00:06:53 Steve Small

That’s quite the visual there, Don.

00:06:55 Steve Small

It makes me think of everyone’s holiday travels at this time.

00:06:57 Steve Small

So as you get ready for big holiday meals, other GERD prevention tips include avoiding meals two to three hours before bedtime, raising the head of the bed for nighttime symptoms, limiting fat intake, avoiding tobacco and trigger foods, including spicy foods.

00:07:14 Don Weinberger

You’re the no fun police, Steve.

00:07:16 Don Weinberger

So I guess I just can’t dip my turkey in hot sauce.

00:07:20 Don Weinberger

All right, got it.

00:07:20 Steve Small

Yep, exactly.

00:07:22 Steve Small

So when it comes to this claim that most GERD cases only need short-term treatment, the verdict is true with conditions.

00:07:33 Don Weinberger

Right.

00:07:34 Don Weinberger

So the practice pearl is to ask two questions.

00:07:38 Don Weinberger

Number one, why is this patient on a PPI?

00:07:41 Don Weinberger

And number two, what’s the plan for it?

00:07:44 Don Weinberger

If someone’s been on a PPI for years,

00:07:46 Don Weinberger

there should be some kind of indication or reason that could be pointed to at the lowest dose that actually controls that patient’s symptoms.

00:07:56 Don Weinberger

And ask about OTC PPIs too, because as you know, you can buy 500 counts off pallets, right?

00:08:02 Don Weinberger

So they can take without even noticing it.

00:08:05 Don Weinberger

And also plan any step down with that prescriber.

00:08:09 Steve Small

Right, pallets of PPIs.

00:08:11 Steve Small

And technicians can help by noticing long-running refills and flagging them to the pharmacist who can start that conversation.

00:08:19 Steve Small

So get our Less Is More resource on chronic meds in older patients to help frame those deprescribing conversations.

00:08:27 Don Weinberger

Less is more, except when it comes to that Thanksgiving stuffing.

00:08:31 Steve Small

Spoken like a man who’s planned his plate.

00:08:35 Don Weinberger

All right, speaking of food and going to the market, when a medication gets pulled off the market, it’s natural to assume, is the whole drug class dangerous?

00:08:48 Don Weinberger

So let’s test that.

00:08:49 Don Weinberger

And the claim is H2 blockers cause cancer.

00:08:55 Steve Small

This is a blast from the past.

00:08:56 Steve Small

This claim is tied to the ranitidine recall.

00:08:59 Steve Small

So let’s start there.

00:09:00 Steve Small

What actually happened back then?

00:09:02 Don Weinberger

Yeah.

00:09:03 Don Weinberger

So in April of 2020, that seems like so long ago, FDA asked manufacturers to withdraw all prescription and over-the-counter ranitidine products.

00:09:13 Don Weinberger

And the reason was a contaminant called N-nitrosodimethylamine or NDMA.

00:09:18 Don Weinberger

I’m going to call it NDMA, so I’m not going to say a long word every single time, but which is considered a probable human carcinogen.

00:09:24 Don Weinberger

And FDA found that the NDMA in ranitidine products increased over time.

00:09:30 Don Weinberger

and at higher storage temperatures.

00:09:32 Don Weinberger

So levels could climb above that acceptable daily limit.

00:09:37 Steve Small

Well, I bet there’s interesting chemistry involved there then.

00:09:40 Don Weinberger

Yeah, so you know me, it’s a chance to get nerdy.

00:09:43 Don Weinberger

Let’s go ahead and do it.

00:09:44 Don Weinberger

So, and I’ll have ask the producer put an image up to help, you know, give a visual explanation.

00:09:50 Don Weinberger

But

00:09:51 Don Weinberger

Ranitidine carries both halves of NDMA in its own structure.

00:09:54 Don Weinberger

You have the dimethylamino group and you have a nitro group.

00:09:59 Don Weinberger

And with heat, you know, heat’s a catalyst with chemistry reactions, right?

00:10:02 Don Weinberger

With heat and time on a shelf, they can combine to form an NDMA.

00:10:07 Don Weinberger

And famotidine and cimetidine don’t have that combination.

00:10:10 Don Weinberger

So this seems to be a ranitidine problem and not an H2 blocker problem.

00:10:15 Steve Small

And it is worth saying, Don, that nizatidine shares that structure, which is why some nizatidine products were recalled too.

00:10:22 Steve Small

The problem was NDMA forming in the product over time, not that every tablet started out dangerous, and it could make more of the contaminant the longer it sat around.

00:10:36 Steve Small

But what about cancer on the people who took ranitidine?

00:10:39 Steve Small

That understandably is scary to patients, right?

00:10:41 Don Weinberger

Definitely so.

00:10:44 Don Weinberger

Pulling in one of the largest studies that we have in 2023, it was a multinational analysis comparing more than 900,000 new ranitidine users with about 275,000 new users of other H2 blockers.

00:10:59 Don Weinberger

And between the groups, cancer rates were about the same.

00:11:02 Don Weinberger

So roughly 16 per 1,000 person years in each group.

00:11:07 Steve Small

Which sounds reassuring, but I’m guessing there are caveats.

00:11:10 Don Weinberger

Yes, there are always caveats, right?

00:11:13 Don Weinberger

And we’re here to say it.

00:11:13 Don Weinberger

So yes, follow up with that was only a few years and it compared ranitidine against other H2 blockers.

00:11:22 Don Weinberger

Keep in mind, other studies have reported small associations with certain cancer sites.

00:11:26 Don Weinberger

So the overall picture is mixed.

00:11:29 Steve Small

Right.

00:11:29 Steve Small

And association isn’t the same thing as causation.

00:11:34 Don Weinberger

Exactly like we say all the time, right?

00:11:36 Don Weinberger

And that brings us to the comeback.

00:11:38 Don Weinberger

In November 2025, FDA approved reformulated ranitidine tablets with manufacturing improvements to address that NDMA formulation during shelf life.

00:11:49 Don Weinberger

But for now, on the shelves, expect only to be on prescription only.

00:11:53 Steve Small

And does that make it cancer risk-free?

00:11:56 Don Weinberger

FDA does not use that wording.

00:11:59 Don Weinberger

However, the labeling does include some new things.

00:12:02 Don Weinberger

So storage instructions, number one is keep the tablets in the original bottle with a desiccant.

00:12:07 Don Weinberger

Open only one bottle at a time because you get multi-bottle packs and discard unused tablets 90 days after first opening or by the expiration date, whichever comes first.

00:12:17 Steve Small

So a comeback tour for ranitidine with a much stricter storage rider, but there’s a pharmacy workflow angle here too.

00:12:25 Don Weinberger

Yep, so there is.

00:12:27 Don Weinberger

That label does ask pharmacists to inform the patient and note a discard after date on that bottle.

00:12:34 Don Weinberger

So keep that in mind.

00:12:36 Don Weinberger

So when it comes back to this claim, it is H2 blockers cause cancer and the verdict is.

00:12:47 Don Weinberger

Rumor.

00:12:48 Steve Small

So it’s a rumor for the whole class, but the story started with the real problem in ranitidine and nizatidine.

00:12:55 Steve Small

Both things can be true.

00:12:57 Don Weinberger

Yep, so that’s the line for patients.

00:12:59 Don Weinberger

FDA’s testing didn’t find NDMA in famotidine or cimetidine.

00:13:04 Steve Small

And for someone who took ranitidine years ago, the largest study so far didn’t find more cancers overall, though no study can promise zero risk here.

00:13:15 Don Weinberger

And if it ain’t broke, don’t fix it.

00:13:17 Don Weinberger

FDA said patients doing well on other H2 blockers or PPIs should talk with a provider before switching.

00:13:24 Don Weinberger

And to help patients navigate confusing headlines,

00:13:26 Don Weinberger

use our Resources for Discussing Medical Misinformation, which pulls together tools for talking about health misinformation.

00:13:33 Steve Small

That is a great chart.

00:13:34 Steve Small

And switching GERD meds is where patients get tangled up and where little rules get passed along almost like family recipes.

00:13:41 Steve Small

So what if a patient is going from an H2 blocker to a PPI?

00:13:47 Steve Small

The claim here is that patients must overlap regimens when switching from an H2 blocker over to a PPI.

00:13:54 Don Weinberger

I see this coming up often.

00:13:55 Steve Small

Same, even in the hospital.

00:13:57 Steve Small

Since this claim touches both prescribing and pharmacology, I reached out to Dr.

00:14:02 Steve Small

Nina Pascua, MD and PharmD, a gastroenterologist at The Oregon Clinic in Portland.

00:14:08 Steve Small

And Don, you may remember her as our guest expert from our July 2026 episode on laxatives.

00:14:14 Don Weinberger

No buts about it.

00:14:15 Don Weinberger

She was a great guest.

00:14:17 Don Weinberger

Excited to hear your thoughts on this.

00:14:22 Steve Small

Welcome back, Dr.

00:14:24 Steve Small

Pascua.

00:14:24 Steve Small

So glad to have you on Rumor vs Truth again to help us with this claim that patients must overlap regimens in switching from an H2 blocker to a PPI.

00:14:34 Steve Small

And I am curious, where do you think this practice comes from here?

00:14:38 Nina Pascua

Yeah, thanks, Steve, for having me back.

00:14:41 Nina Pascua

So I think it has to do with people understanding somewhat of the mechanism of action of the proton pump inhibitors.

00:14:49 Nina Pascua

So the way I sort of

00:14:52 Nina Pascua

tell patients on how the mechanism of action works is by visualizing the cell where everything sort of happens in the stomach.

00:15:02 Nina Pascua

So essentially you have this proton pump at the end of what they call the parietal cell.

00:15:08 Nina Pascua

And that’s what churns hydrogen ions out into the stomach and creates that acid.

00:15:16 Nina Pascua

Then on the other side of that parietal cell, you have a histamine receptor.

00:15:21 Nina Pascua

And that histamine receptor is inhibited essentially by the histamine receptor antagonists.

00:15:27 Nina Pascua

And that then leads to a cascade down to the proton pump to reduce the hydrogens being released to create that acid.

00:15:36 Nina Pascua

Now, when you think about a proton

00:15:39 Nina Pascua

pump inhibitor that works directly on that proton pump rather than waiting for that cascade from the H2 receptor antagonist.

00:15:47 Nina Pascua

And so that’s why we know that the proton pump inhibitors are much more effective in reducing gastric secretion as opposed to the H2 or the histamine receptor inhibitors or histamine receptor antagonists.

00:16:02 Nina Pascua

Now, where this rumor has come from is essentially because

00:16:07 Nina Pascua

It’s been found that the proton pump inhibitors take about two to three days for a full effect.

00:16:14 Nina Pascua

Now, why is that?

00:16:16 Nina Pascua

Well, it’s because not all proton pumps in the stomach are activated at once.

00:16:23 Nina Pascua

And so the proton pump inhibitors only work on those that are active.

00:16:29 Nina Pascua

And that’s part of the rationale as to why it’s recommended that you take your proton pump inhibitor, like omeprazole or pantoprazole, prior to a meal because the food stimulates those proton pumps to be active.

00:16:44 Nina Pascua

You don’t need the H2 receptor antagonist to inhibit the histamine receptor because the proton pump inhibitor has already irreversibly inhibited that proton pump.

00:16:57 Nina Pascua

So it’s really not effective.

00:16:59 Nina Pascua

And that’s what in research studies, they’ve actually found that the addition of an H2 receptor antagonist as overlap really doesn’t

00:17:08 Nina Pascua

result in necessarily faster symptom relief as long as you’re taking the proton pump inhibitor correctly.

00:17:15 Nina Pascua

Now, the one area where studies have shown that it perhaps may be effective is in reducing nighttime acid breakthrough.

00:17:27 Nina Pascua

And so in studies, they found that for those taking a proton pump inhibitor once daily in the morning, they may get

00:17:38 Nina Pascua

the nighttime breakthrough acid reflux and taking an H2 receptor antagonist like famotidine could reduce that nighttime acid reflux in the first seven days of proton pump inhibitor use.

00:17:55 Nina Pascua

But after seven days, they found that there wasn’t much difference in the symptoms in patients.

00:18:03 Steve Small

Interesting.

00:18:04 Steve Small

So a very select case of patients with this certain condition.

00:18:08 Steve Small

And otherwise, we couldn’t find a lot of evidence for or against overlapping in other cases, but based on what you’re saying, it does sound like it’s more complicated than it needs to be by having this overlap.

00:18:19 Steve Small

You’ve got to make sure you start one med, stop one med, and make sure you don’t leave them on long term, right?

00:18:25 Nina Pascua

And a lot of patients when they’re dealing with

00:18:29 Nina Pascua

two medications, they can often get them confused.

00:18:33 Nina Pascua

It’s not uncommon for patients to be like, well, I think I’m on an acid reducer, acid inhibitor.

00:18:37 Nina Pascua

It’s used interchangeably out there.

00:18:40 Nina Pascua

And then they don’t, they might take sort of one in the morning and then one

00:18:46 Nina Pascua

at night.

00:18:47 Nina Pascua

And oftentimes they’ll take sometimes the proton pump inhibitor at night before going to bed.

00:18:54 Nina Pascua

And again, that’s not going to be effective because it’s not being taken before a meal, where again, the meal helps to stimulate that proton pump inhibitor effect.

00:19:04 Steve Small

Right.

00:19:05 Steve Small

Too many drugs, too many cooks in the kitchen, too many meds on people’s plates.

00:19:10 Steve Small

It sounds like Thanksgiving already.

00:19:12 Steve Small

So thank you so much for helping us delve into this claim here.

00:19:17 Steve Small

And I’ll share this with Don to see what he thinks.

00:19:19 Steve Small

And we wish you and your GI team a happy GERD Awareness Week.

00:19:23 Nina Pascua

Thank you.

00:19:29 Don Weinberger

That was a really good interview, Steve.

00:19:30 Don Weinberger

I like her point that a PPI works directly on the proton pump, so you don’t necessarily need an H2 blocker running in the background while that PPI gets up to speed.

00:19:41 Steve Small

Right, and timing matters more than overlap, probably.

00:19:44 Steve Small

Even though pantoprazole’s labeling says it can be taken without regard to meals, ACG generally recommends taking PPIs 30 to 60 minutes before a meal because, as we said, food activates the pumps it targets.

00:19:58 Steve Small

And

00:19:58 Steve Small

take it at bedtime and it may not work as well as a dose before dinner.

00:20:02 Don Weinberger

Yeah, just take it at the right time to get the best bang for your buck.

00:20:06 Steve Small

Right, so when it comes to this claim that patients must overlap regimens when switching from an H2 blocker to a PPI, the verdict is rumor with conditions.

00:20:20 Don Weinberger

Okay, so let’s go ahead and shuck that claim for another pearl, right?

00:20:23 Don Weinberger

We have start one and stop one, but there isn’t data to say an overlap is harmful either.

00:20:29 Steve Small

Right, and if we do overlap, the old med needs a clear end date. We don’t want patients on 2 acid reducers indefinitely and unintentionally. And counsel on the basics. Take the PPI before a meal and make sure patients know which pill is which. As Dr. Pascua said, patients often use acid inhibitor interchangeably.

00:20:49 Don Weinberger

Good points. And technicians can help by asking what acid medicines a patient takes and when. And flagging an H2 blocker plus a PPI with no stop date to their pharmacist. And also whether to overlap or switch or taper is the pharmacist or prescriber’s call. Oh, Steve, don’t think I forgot about your gift quip earlier.

00:21:14 Don Weinberger

So what’s going on?

00:21:16 Steve Small

Well Don, I can never forget about you. So you asked about tapering PPIs, right? That point has been a controversial stomachache for eons. And I did have a chance to ask Dr. Pascua what she thought. Okay.

00:21:28 Nina Pascua

In reality, there is a little bit of truth to this. And again, it gets to the mechanism of action of the PPIs. And so what happens essentially is that when you take a PPI,

00:21:41 Nina Pascua

on a chronic basis. Again, it reduces that acid secretion, which then the increased gastric pH, again, reduced acid, increased pH, reduces that negative feedback on the gastrin hormone release.

00:21:56 Nina Pascua

And so that you have then increased gastrin floating around or increased gastrin secretion because again, there’s no negative feedback loop. So when you stop the proton pump, you have that increased gastrin, which then stimulates certain cells to increase the histamine mediated acid secretory sort of capacity. It increases that acid. But that’s only very, very temporarily. And I think people take it a little bit too far.

00:22:27 Nina Pascua

So you don’t need this really long taper of a proton pump inhibitor in actuality. And so I think that it might be, again, getting patients to do something that’s a little bit more complicated than they actually need. And you can abruptly discontinue. I think where

00:22:48 Nina Pascua

where the fear lies is that, oh my goodness, I’m going to go through withdrawal. They almost make it sort of equivalent to like steroids where you do have to taper because, or like an anxiolytic where you do have to taper because you will get withdrawal. In this case, you actually don’t get withdrawal. You’re really just getting the effect of that increased sort of gastrin. And again, it’s only temporary.

00:23:18 Don Weinberger

Wow, another solid hit there. So tapering a PPI isn’t a must. I can stomach that.

00:23:25 Steve Small

That’s good to hear. And there’s the option to add an as needed H2 blocker or antacid like milk of magnesia or, you know, calcium carbonate tabs for temporary rebound symptoms. You know, some studies even used PPIs as needed here as well.

00:23:38 Don Weinberger

Yep, and I’ll go and plug another resource of ours. We can help sort out tapering approaches

00:23:43 Don Weinberger

for other meds using our Common Oral Medications that May Need Tapering chart has all the details you need. All right, let’s zoom on in to everybody’s favorite segment, which is Fast Facts.

00:24:00 Steve Small

This is where we jump into some common bite-sized claims about GERD medications and give them a seal of approval or debunk them quickly. So first up here, the claim is proton pump inhibitors cause dementia, and the verdict is rumor.

00:24:14 Don Weinberger

So some observational studies show there’s an association with dementia, but it’s not that PPIs are the cause of it. And the umbrella review found no overall link in 10 out of 11 systematic reviews and meta-analyses. Though, to be honest, the authors rated the certainty as low. Keep in mind, some observational studies have also found a link between H2 blocker use and dementia, but they still can’t prove causality.

00:24:43 Don Weinberger

Still, every long-term PPI, you should have a reason and use the lowest dose and shortest duration possible.

00:24:51 Steve Small

So get our Comparison of Proton Pump Inhibitors chart, which lists the approved indications and dosing to help you when you’re reviewing a patient’s PPI.

00:24:59 Don Weinberger

Okay, next claim is intermittent PPI doses work better than continuous IV PPIs for bleeding ulcers. The verdict is rumor with conditions.

00:25:09 Steve Small

Yeah, this is a great hospital topic. So after endoscopic control of bleeding, ACG recommends high dose PPI therapy given continuously, like 80 milligrams once, then 8 milligrams per hour, or intermittently, like 80 milligrams once, then 40 milligrams every 12 hours. And you do that for three days to prevent rebleeding.

00:25:30 Steve Small

Both approaches have similar reductions in re-bleeding and mortality, but the conditions here, intermittent dosing may be less costly, mean less workload for pharmacy and nurses, and potentially less fluid exposure.

00:25:42 Don Weinberger

Yeah, good points. I’m glad I threw you that turkey bone with the hospital claim. And patients usually continue PPIs for at least two more weeks after this high dose therapy. So expect them on med lists at transfer and discharge.

00:25:58 Don Weinberger

For those smooth handoffs, check out our Transitions of Care Checklist.

00:26:07 Steve Small

Well, we really shoveled those in, Don, but that was a nice way to cool things down before our last claim here.

00:26:14 Don Weinberger

I know. Let’s go ahead and get cool and be gentle about things. So it’s easy to assume the gentler sounding option must be safer, especially with all the PPI headlines that are out there. So with that, let’s look at our last claim.

00:26:26 Don Weinberger

which is H2 blockers are safer than PPIs long-term.

00:26:30 Steve Small

Okay, so is safer just fewer, scarier headlines? Is that what they mean?

00:26:36 Don Weinberger

That’s part of it. You know, PPIs have a long list, ingredient list, if you will. You know, we have fractures, we have kidney disease, we have dementia, we have vitamin B12 deficiency, we have infections. But most of those come from observational studies.

00:26:53 Don Weinberger

which the ACG guideline says they have flaws, aren’t definitive, and they just don’t establish cause and effect.

00:27:01 Steve Small

So there could be links, but we can’t prove these are side effects. What does the stronger evidence say here?

00:27:08 Don Weinberger

Okay, so stronger, the best randomized data is a trial of over 17,000 older adults with heart or artery disease that compare pantoprazole versus placebo over a median of three years. And of the harms they looked at,

00:27:23 Don Weinberger

The only one that stood out was the gastrointestinal infections. It was 1.4% versus 1% for a number needed to harm of 250.

00:27:33 Steve Small

So 250 people would need to take pantoprazole for about 3 years to see one extra infection. That said, PPIs aren’t risk-free, but the scary list doesn’t hold up well when we start looking at randomized trials. But what about H2 blockers? Are they safer?

00:27:51 Don Weinberger

These are not risk-free either. They can cause central nervous system effects like confusion. Cimetidine has its own side effects interactions and NDMA is why ranitidine was pulled. And we couldn’t find a head-to-head long-term safety trial of those two classes.

00:28:08 Steve Small

And you know, then there’s the question of how well they work.

00:28:12 Don Weinberger

That’s the catch. Balancing risks versus benefits. So in erosive esophagitis,

00:28:17 Don Weinberger

Standard dose H2 blockers heal about 40% of the cases compared to 18 to 20% on placebo and PPIs do considerably better. ACG strongly recommends a PPI over an H2 blocker for healing and maintenance since PPIs generally heal at 12% a week compared to 6% for H2 blockers.

00:28:37 Steve Small

Yeah, that’s an interesting difference. Plus, we know H2 blockers can lose their effect with regular use called tachyphylaxis.

00:28:45 Steve Small

That tolerance can show up in as little as two days. So a safer drug that doesn’t heal the esophagus isn’t much of a trade.

00:28:53 Don Weinberger

Right. So where H2 blockers shine is mild or intermittent symptoms or on-demand relief, step down in non-erosive disease, or as an as-needed rescue after stopping a PPI.

00:29:06 Steve Small

And the American Gastroenterological Association’s advice is to not swap or stop a PPI just to dodge side effects.

00:29:14 Steve Small

Stop it if there’s no indication, but people with Barrett’s, severe esophagitis, strictures, or high GI bleeding risk generally shouldn’t be deprescribed, as we talked about earlier.

00:29:25 Don Weinberger

All good points. So when it comes back to the claim that H2 blockers are safer than PPIs long term, the verdict is rumor with conditions.

00:29:40 Steve Small

And the key is to use the right drug, the lowest effective dose for the shortest duration with an appropriate reason on file. So safer on a headline isn’t the same as safer for that patient. If a patient asks to switch to an H2 blocker because of something they read, find out what they’re worried about first and loop in the prescriber if the indication is severe.

00:30:01 Don Weinberger

If the patient worries about their kidneys or bones, AGA doesn’t recommend routine creatinine or bone density checks just because someone takes a PPI.

00:30:10 Don Weinberger

and standard age-based screening and getting recommended daily calcium and vitamin D still do apply.

00:30:16 Steve Small

I like that. Standard screening can help ease concerns. And with that, let’s ease our way to our bottom line truth, which is that GERD meds aren’t always lifelong, and theoretical fears don’t replace an indication, match the dose, drug, and duration of the patient.

00:30:35 Don Weinberger

So the broad truth is that GERD meds deserve

00:30:38 Don Weinberger

neither blind loyalty nor blind fear. Some select patients truly need them long term, while others can step down with a plan. And most of those scary sounding claims, you know, from cancer to dementia, rest on associations that have not been shown to be a cause and effect.

00:30:56 Steve Small

And the practical takeaway, check the indication, use the lowest effective dose, and have a plan for stopping or switching, which is what we should do with every med, right?

00:31:07 Don Weinberger

Very true. Now that we gobbled up these GERD claims, claim CE credit and access evidence-based resources in Pharmacist’s Letter, Pharmacy Technician’s Letter, or Prescriber Insights.

00:31:18 Steve Small

And if you’re not yet a subscriber or want to upgrade, save 10% with our exclusive listener code RVT1026 at checkout. There is an easy link in the show notes.

00:31:29 Don Weinberger

If you are a subscriber, tap the claim credit link in the show notes or search your CE organizer for this episode.

00:31:35 Steve Small

And if you have a GERD question, a question about GI meds, or a good heartburn story, send us a message.

00:31:42 Don Weinberger

Email us at [email protected] or you send us fan mail in the podcast show notes.

00:31:48 Steve Small

And join us next time or we’ll dig into weight loss meds just in time for New Year’s resolutions.

00:31:54 Don Weinberger

We’ll be weighing the evidence, so no need to wait until January to get the facts. Thank you for joining us on Rumor vs Truth, your trusted source for facts.

00:32:02 Don Weinberger

where we dissect the turkey of evidence behind risky rumors and real clinical truths.

00:32:06 Steve Small

We’ll see you next time.

Rumor vs Truth

Rumor vs Truth Podcast: Full Episode History

Rumor vs Truth: Full Episode History